Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Policy / Regulatory

China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value

Fineline Cube Apr 24, 2024

The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...

Company Drug

China Medical System Holdings’ Desidustat NDA Accepted for Review by China’s NMPA

Fineline Cube Apr 24, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...

Company Drug

Akeso Biopharma Submits sNDA for Cadonilimab in Cervical Cancer to China’s CDE

Fineline Cube Apr 24, 2024

China-based Akeso Biopharma (HKG: 9926) has announced the submission of a supplementary New Drug Application...

Company Drug

Huadong Medicine’s HDM1005 Receives US FDA Clinical Trial Approval for Weight Management

Fineline Cube Apr 23, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial...

Company Drug

Sandoz’s Partner Samsung Bioepis Scores EC Approval for Stelara Biosimilar Pyzchiva

Fineline Cube Apr 23, 2024

Switzerland-headquartered Sandoz (SWX: SDZ) has announced that the European Commission (EC) has granted approval for...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Go-Ahead for Camrelizumab Combination Therapy Study in Pancreatic Cancer

Fineline Cube Apr 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center

Fineline Cube Apr 23, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has...

Company Drug

CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial

Fineline Cube Apr 23, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial...

Company Drug

CANbridge Pharmaceuticals’ CAN008 Fails to Meet Phase II Endpoints in Glioblastoma Multiforme

Fineline Cube Apr 23, 2024

CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept)...

Company Deals R&D

Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research

Fineline Cube Apr 23, 2024

Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research...

Company Deals

Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software

Fineline Cube Apr 23, 2024

Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic...

Company Drug

GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti

Fineline Cube Apr 23, 2024

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment

Fineline Cube Apr 23, 2024

French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of...

Company

Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...

Company Deals

Genrix Biopharmaceutical Partners with China Resource Medicine for Expanded Market Coverage

Fineline Cube Apr 23, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a...

Company Deals

Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture

Fineline Cube Apr 23, 2024

Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...

Company

GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues...

Company Deals

Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access

Fineline Cube Apr 23, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a...

Company

Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits

Fineline Cube Apr 23, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as...

Policy / Regulatory

China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration

Fineline Cube Apr 23, 2024

The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...

Posts pagination

1 … 371 372 373 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.